Michelle Giddings, APRN
Psychiatric/Mental Health · Las Vegas, NVNPI 1336303072
Payments from drug & device makers
Across 933 payments — averaging $140.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$49K
- E.r. Squibb & Sons, L.L.C.$42K
- Axsome Therapeutics, Inc.$28K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$1K
- plus $7K from 24 others
What the payments were for
- Consulting fees$24,76819%
- Speaking & faculty fees$70,97454%
- Travel & lodging$15,80612%
- Food & beverage$19,57715%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 148 | $49,163 |
| E.r. Squibb & Sons, L.L.C. | 77 | $42,067 |
| Axsome Therapeutics, Inc. | 61 | $27,611 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 106 | $2,122 |
| AbbVie | 77 | $1,512 |
| Supernus Pharmaceuticals, Inc. | 122 | $1,455 |
| Alkermes, Inc. | 52 | $1,264 |
| Neurocrine Biosciences, Inc. | 41 | $1,050 |
| Johnson & Johnson | 45 | $1,016 |
| Teva Pharmaceuticals USA, Inc. | 45 | $865 |
| Lundbeck LLC | 31 | $609 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $403 |
| Sunovion Pharmaceuticals Inc. | 25 | $349 |
| Corium, LLC | 17 | $290 |
| Almatica Pharma LLC | 14 | $249 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $228 |
| Avanir Pharmaceuticals, Inc. | 11 | $195 |
| Vanda Pharmaceuticals Inc. | 8 | $178 |
| Eisai Inc. | 6 | $113 |
| Bioxcel Therapeutics, Inc. | 2 | $113 |
| Neuronetics, Inc. | 5 | $109 |
| Bausch Health US, LLC | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Sage Therapeutics, LLC | 1 | $44 |
| Merck | 2 | $40 |
| Alfasigma USA, Inc. | 2 | $39 |
| Tris Pharma Inc | 1 | $32 |
| Tempus AI, Inc | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$47,164
- COBENFY$29,033
- Auvelity$26,220
- LYBALVI$465
- CAPLYTA$371
- VRAYLAR$248
- ABILIFY MYCITE$125
- ABILIFY MAINTENA$122
- ABILIFY ASIMTUFII$122
How this compares
$131,303 in reported general payments places this provider in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $92,904 |
| RexultiBrexpiprazole | 21 | $32,390 |
| LatudaLurasidone Hcl | 12 | $16,407 |
| SeroquelQuetiapine Fumarate | 14 | $8,214 |
| DayvigoLemborexant | 20 | $6,592 |
| Adderall XrDextroamphetamine/Amphetamine | 15 | $5,771 |
| Quetiapine Fumarate | 255 | $5,555 |
| Chlorpromazine Hcl | 23 | $5,081 |
| BelsomraSuvorexant | 12 | $5,080 |
| Risperidone | 268 | $4,480 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $3,471 |
| Hydroxyzine Hcl | 207 | $3,246 |
| Oxcarbazepine | 58 | $3,140 |
| Carbamazepine ErCarbamazepine | 20 | $2,864 |
| Topiramate | 178 | $2,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,050 | $92,90411 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49,163 | $32,39021 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $349 | $16,40712 claims |
| Eisai Inc.Dayvigo | $113 | $6,59220 claims |
| MerckBelsomra | $40 | $5,08012 claims |
| Almatica Pharma LLCSertraline Hcl | $249 | $1,700147 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $865 | $1,55130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Las Vegas
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
- Sydney EganLas Vegas$14K
- Ma Victoria EscardaLas Vegas$12K
- Carminia SalvacionLas Vegas$12K
- Valentina AkohLas Vegas$12K
- Angela WilsonLas Vegas$11K
- Michael MathisenLas Vegas$10K
- Edina BorosLas Vegas$9K
- Salem FitsumLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.